OrbiMed Advisors IMA Position
Active4-Fund ConvergenceOrbiMed Advisors held their position in ImageneBio, Inc. (IMA) in Q4 2025, holding $22.7M worth of shares across 6,589,455 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
IMA is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
About ImageneBio, Inc.
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
Full company profile →OrbiMed Advisors IMA Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 6,589,455 | — | $22.7M |
| Q3 2025 | Decreased | 6,589,455 | -5,459,318 | $15.6M |
| Q2 2025 | Held | 12,048,773 | — | $13.1M |
| Q1 2025 | Held | 12,048,773 | — | $12.5M |
| Q4 2024 | Held | 12,048,773 | — | $17.7M |
| Q3 2024 | Held | 12,048,773 | — | $22.8M |
| Q2 2024 | Held | 12,048,773 | — | $32.1M |
| Q1 2024 | Held | 12,048,773 | — | $36.0M |
| Q4 2023 | Held | 12,048,773 | — | $36.8M |
| Q3 2023 | Increased | 12,048,773 | +153,121 | $45.1M |
| Q2 2023 | Held | 11,895,652 | — | $66.3M |
| Q1 2023 | New | 11,895,652 | +11,895,652 | $53.8M |
Frequently Asked Questions
Does OrbiMed Advisors own IMA?
Yes. As of Q4 2025, OrbiMed Advisors holds 6,589,455 shares of ImageneBio, Inc. (IMA) valued at $22.7M. This data comes from their SEC 13F filing.
How many hedge funds own IMA?
4 specialist biotech hedge funds currently hold IMA, including Deep Track Capital, BVF Partners, RTW Investments. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy IMA?
OrbiMed Advisors's position in IMA was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's IMA position increasing or decreasing?
OrbiMed Advisors held their IMA position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
IMACompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →